The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies
Abstract
OBJECTIVE: These studies were designed to evaluate the efficacy and tolerability of the first nonpeptide vasopressin V(1b) receptor antagonist, SSR149415, in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). METHOD: Studies were randomized 8-week, double-blind, placebo-controlled trials evaluating 100- and 250-mg twice daily doses of SSR149415, placebo, and escitalopram 10 mg/day or paroxetine 20 mg/day, conducted from August 2006 through February 2008. Participants met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for MDD or GAD. Baseline Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HDRS) total scores were ≥ 24 and 18, respectively, and in the GAD trial baseline Hamilton Anxiety Rating Scale (HARS) score was ≥ 22. Primary efficacy variables included changes from baseline in total score on HDRS or HARS and MADRS, and the secondary variable included changes in the Clinical Global Impressions-Severity of Illness score (CGI-S). A 4-week, double-blind, placebo-controlled study evaluating the effect of 100- and 250-mg twice daily doses of SSR149415 on the hypothalamic-pituitary-adrenal (HPA) axis in MDD patients was also conducted. RESULTS: In the GAD trial, SSR149415 did not separate from placebo on the primary (HARS-100 mg: P = .29; 250 mg: P = .21) and secondary (CGI-S-100 mg: P = .18; 250 mg: P = .24) outcome measures, while paroxetine demonstrated efficacy (HARS: P = .003; CGI-S: P = .01). In 2 MDD trials, SSR149415-treated patients did not show significant improvement from baseline on any outcome measure compared with placebo-treated patients (HDRS-100 mg: P = .21 and .48, respectively; 250 mg: P = .22 and P = .46, respectively; CGI-S-100 mg: P = .64 and P = .82, respectively; 250 mg: P = .33 and P = .08, respectively). In the third MDD study, SSR149415 250 mg (P = .04), but not escitalopram (P = .15), demonstrated significant improvement compared to placebo on the HDRS total score at week 8. SSR149415 had no deleterious effects on the HPA axis. CONCLUSIONS: These studies demonstrate that SSR149415 may not be useful for the treatment of GAD and that its antidepressant potential needs to be further evaluated. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00374166 (Sanofi ID number: DFI5880), NCT00361491 (Sanofi ID number: DFI5879), NCT00358631 (Sanofi ID number: DFI5878), NCT01606384 (Sanofi ID number: PDY5467).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another trial with 100 mg and 250 mg SSR149415 did not show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [86]
In the citing paper
“however, the trial failed because the comparator escitalopram did not achieve a significant reduction in the HDRS.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [86]
In the citing paper
“Interestingly, SSR149415 with dosage up to 250 mg did not reduce the cortisol response to the CRH challenge, while doses higher than 250 mg significantly reduced the cortisol response.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [86]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
A stagewise rejective multiple test procedure based on a modified Bonferroni test
HOMMEL, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
A Unified Approach to Mixed Linear Models
McLean, R. A., Sanders, W. L., & Stroup, W. W. (1991) · The American Statistician · doi:10.1080/00031305.1991.10475767 · Cited by 601
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Self-citationPurba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Role of neuropeptides in anxiety, stress, and depression: From animals to humans
Kormos, V., & Gaszner, B. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.014 · Cited by 329
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
Rutigliano, G., Rocchetti, M., Paloyelis, Y., Gilleen, J., Sardella, A., Cappucciati, M., Palombini, E., Dell’Osso, L., Caverzasi, E., Politi, P., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.117 · Cited by 149
“…there is also growing interest in the potential for synthetic neuropeptides in treatment of psychosis (for a comprehensive review see (Gumley et al., 2014)), autism spectrum disorders (ASD) (Thompson et al., 2006; Uzunova et al., 2015), and affective and anxiety disorders (Griebel et al., 2012).”
BackgroundMethod
Metadata
- Authors
- Griebel, G., Beeské, S., & Stahl, S. M.
- Affiliations
- Sanofi (France) (FR)
- Corresponding author
- Griebel, Guy
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2012-10-16
- Volume
- 73
- Issue
- 11
- Pages
- 1403-1411
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2061265867
- Cited by
- 81
- References
- 22
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 8 · 2023: 3 · 2022: 2 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 10 · 2013: 7 · 2012: 1
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- major depressive disorder, generalized anxiety disorder, antidepressant efficacy, tolerability, paroxetine, escitalopram, hypothalamic-pituitary-adrenal axis, placebo comparison, dose comparison
- MeSH terms
- Adolescent, Adult, Antidepressive Agents, Anxiety Disorders, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Indoles, Male, Middle Aged, Pyrrolidines, Recurrence, Anti-Anxiety Agents, Citalopram, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, Paroxetine, Young Adult, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies. https://app.cochat.ai/papers/10.4088/jcp.12m07804
- The paper
- Griebel, G., Beeské, S., & Stahl, S. M. (2012). The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.12m07804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.